GSK, University of Edinburgh partner in drug discovery
GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis.
The alliance will build on work by university researchers that recently uncovered a molecular mechanism believed to have a major role in triggering life-threatening multiple organ failure.
Work on the project will be carried out both within GSK and at the college of medicine and veterinary medicine located at the Edinburgh BioQuarter, Scotland's flagship life sciences development.
Under the terms negotiated by the BioQuarter, the University will receive success-based financial support from GSK linked to reaching agreed milestones, as well as an undisclosed upfront payment and royalties on sales from any product that is successfully commercialized out of the collaboration.
Upcoming Events
-
23Apr
-
07May
-
14May